Helius Medical (HSDT) Technologies announced the establishment of Revelation Neuro, its wholly-owned private subsidiary focused on the development of non-implantable AI powered BCI technology. “We are thrilled to establish Revelation Neuro to pursue the development of a new gold standard of care for personalized neurorehabilitation using a non-implantable AI powered BCI combining our newly developed intellectual property with Helius’ existing IP. Our technology relies on its proven ability to modulate known target brain processes and trigger therapeutic responses by using translingual stimulation without risky implantation. We believe Revelation Neuro’s BCI technology will be a unique and less invasive therapeutic option,” said Dane Andreeff, Helius President and Chief Executive Officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSDT:
- Helius Medical announces first reimbursement for PoNS Device
- Helius Medical files to sell 6.21M shares of common stock for holders
- Helius Medical Secures Funds Through Warrant Agreements
- Helius Medical announces statistically significant find in DGI in PoNSTEP study
- Helius Medical completes, exceeded target enrollment for stroke study